Bradley J. Monk, MD, FACS, FACOG; David O’Malley, MD; Ursula Matulonis, MD; Shannon N. Westin, MD, MPH; and Matthew Powell, MD, highlight common biomarkers and the importance of molecular testing in the management of advanced ovarian cancer.
Просмотров: 52 OncLiveTV
Santo Nicosia, M.D., M.S., and Patricia Kruk, Ph.D., University of South Florida. Drs. Nicosia and Kruk are CDMRP-funded investigators supported by the DoD Ovarian Cancer Research Program (OCRP). Dr. Nicosia is collaborating with Dr. Kruk and other investigators to validate several urinary proteins as biomarkers for detection of early stage ovarian cancer.
Просмотров: 274 CDMRP
Pre-register at http://Kwatsi.com to enter the Kwatsi iPad giveaway for a chance to win one of three iPads. Ovarian cancer expert, Professor Hani Gabra discusses the Importance and limitations of CA125 as a diagnostic biomarker for ovarian cancer. Hani Gabra is a Professor of Medical Oncology at Imperial College London, based at its Hammersmith Campus. His clinical work is conducted at the Hammersmith Hospital and the Queen Charlotte Hospital for Women. He runs a large evidence based/research led clinical practice providing medical oncology services for women with gynaecological cancer, embedded within a comprehensive large multidisciplinary team. He also provides a clinical trials service encompassing all phases of clinical research, and has interests in upper gastrointestinal cancer and adenocarcinoma of unknown primary. He is chief of service of the West London Gynaecological Cancer Centre based at Queen Charlotte's/Hammersmith Hospital.He is also head of the Section of Molecular Therapeutics in the Department of Oncology at Imperial College and Director of the Ovarian Cancer Action (HHMT) Research Unit, a core funded research unit based at Imperial College London. He has an additional role as Strategic Theme Leader for Cancer Research at Imperial College. Kwatsi was founded in 2010, it is aimed at making knowledge social and more accessible for all. The name Kwatsi is derived from the Ho Indian term which means "to overcome". Kwatsi will launch its website in Summer 2011 at http://Kwatsi.com Kwatsi's mission is to make knowledge sharing rewarding and universally accessible.
Просмотров: 1287 KwatsiLimited
If you're a patient interested in receiving cancer immunotherapy, you might hear the word "biomarkers" come up. They are an increasingly important area of study within the field of cancer immunotherapy research. These biological "signals" provide many clues for doctors to help them identify which patients are more likely to benefit from treatment and the duration of that benefit. In this webinar for patients and caregivers, Dr. Haidong Dong of the Mayo Clinic, discusses the role biomarkers play in making treatment decisions, and delves into the latest research to identify new biomarkers. This webinar was recorded Tuesday, August 29, 2017. The "Cancer Immunotherapy and You" webinar series is produced by the Cancer Research Institute and is made possible with generous support from Bristol-Myers Squibb, Genentech, Regeneron, and Advaxis. Browse our Cancer Immunotherapy and You Webinar Series playlist here on YouTube to see other webinars in this series.
Просмотров: 18590 Cancer Research Institute
Exosomes as Biomarkers of the Genetic Status of Brain Tumors Lecture by Xandra O. Breakefield, PhD Massachusetts General Hospital Cancer Center, Harvard Medical School
Просмотров: 6426 TheOncologistJournal
With the aid of biomarkers to guide doctors’ decision making, patients can be paired with the treatments most likely to benefit them. In this webinar for patients and caregivers, Kunle Odunsi, M.D., Ph.D., of the Roswell Park Comprehensive Cancer Center discusses how biomarkers are already being used to help patients today as well as how we’re working to harness the full potential of biomarkers moving forward. Over the past decade, immunotherapy has provided remarkable benefits for cancer patients, and a number of new immune-based approaches that have been developed provide the possibility of relief for many more patients. However, figuring out which immunotherapy strategy will work best for a particular patient remains challenging. That’s where biomarkers, which can shed light on an individual patient’s biology, come in. Dr. Kunle Odunsi is currently the deputy director, the chair of the Department of Gynecologic Oncology, the M. Steven Piver professor of gynecologic oncology, and the executive director of the Center for Immunotherapy at the Roswell Park Comprehensive Cancer Center, and a professor of gynecology & obstetrics at the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo. As a recognized leader in the field of ovarian cancer immunotherapy, Dr. Odunsi has led several clinical trials involving novel immune-based approaches such as vaccines, while his lab focuses on the molecular characterization of tumor antigens in ovarian cancer and refining strategies to target them more effectively. The "Cancer Immunotherapy and You" webinar series is produced by the Cancer Research Institute and is made possible with generous support from Bristol-Myers Squibb, with additional support from Regeneron, Sanofi Genzyme, and Adaptimmune. Browse our Cancer Immunotherapy and You Webinar Series playlist on YouTube or visit the Webinars page on our website to see other webinars in this series. https://www.cancerresearch.org/webinars
Просмотров: 18625 Cancer Research Institute
Dr. Kunle Odunsi, Chair, Department of Gynecologic Oncology The M. Steven Piver Professor of Gynecologic Oncology & Executive Director, Center for Immunotherapy, Roswell Park Cancer Institute discusses the role of immunotherapy and combination therapy in ovarian cancer, with Ovarcome. Talk About Ovarian Cancer. TOGETHER, we can Ovarcome!
Просмотров: 54 Ovarcome Non-Profit
Presented By: Dr. Malte Buchholz - Head of Basic Research, Clinic for Gastroenterology, University of Marburg Speaker Biography: Malte Buchholz obtained his PhD in molecular biology at the University of Goettingen, Germany, in 1998. He is group leader and Head of Basic Research at the Department of Gastroenterology, Endocrinology and Metabolism, University Hospital Marburg, Philipps-University of Marburg, Germany (http://www.uni-marburg.de/fb20/gastroendokrinol/forschung?language_sync=1). His research interests focus on transcriptome analyses and molecular diagnostics of gastrointestinal tumors, functional genomic analyses of pancreatic cancer, and molecular determinants of tumor-host interactions. Among others, he has performed global gene expression analyses of stromal cell populations from different organs as well as microdissected tumor cells and pre-neoplastic lesions from pancreatic ductal adenocarcinoma (PDAC) patients. These data formed an important basis for the design of specialized cDNA arrays which are suitable to distinguish between different forms of pancreatico-biliary tumors with high diagnostic precision. Webinar: The essential role of miRNA and mRNA on cancer progression and biomarker discovery Webinar Abstract: MicroRNAs (miRNA) are a class of small non-coding RNAs (approximately 21 nt long) that bind complementary sequences in target mRNAs to specifically regulate gene expression. miRNAs play important roles in regulation of gene expression during cell development, differentiation, proliferation and apoptosis. Misregulation of miRNAs and their targets has been associated with several diseases including cancer. The interplay between miRNA and mRNA has been found to be important in cancer development and progression. Simultaneous expression studies of miRNA and mRNA can be valuable in understanding molecular mechanisms that may potentially have an underlying role in various diseases. In this webinar, we demonstrate the technical verification of a novel method to reverse transcribe and pre-amplify miRNA and mRNA from sample limiting serum research samples using TaqMan® Advanced miRNA cDNA synthesis Kit. Based on results from previous studies and unpublished data, Dr. Buchholz’s research group identified a signature of 49 mRNA and 37 miRNA targets that may help to distinguish between benign and malignant pancreatic tissues in the future. In this study these previously identified miRNA and mRNA targets have been used to study expression pattern differences in serum from Normal and Test samples. These miRNA and mRNA targets were spotted on Custom TaqMan array cards to facilitate investigation of 4 samples on each card. Initial results indicate that miRNA and mRNAs can be reliably quantified from a single reverse transcription reaction. Learning Objectives: -Study of miRNAs in Oncology Gene Expression -Understanding the interplay between miRNA and mRNA impacts cancer development and progression -Use of Data Analysis tools for Gene Expression studies involving miRNA and mRNA -Understanding molecular mechanisms that may potentially have an underlying role in various diseases Sponsored By: Thermo Fisher Scientific - Applied Biosystems Earn PACE Credits: 1. Make sure you’re a registered member of LabRoots (https://www.labroots.com/ms/webinar/essential-role-mirna-mrna-cancer-progression-taqman) 2. Watch the webinar on YouTube or on the LabRoots Website (https://www.labroots.com/ms/webinar/essential-role-mirna-mrna-cancer-progression-taqman) 3. Click Here to get your PACE credits (Expiration date – November 15, 2019 09:00 AM): https://www.labroots.com/credit/pace-credits/2488/third-party LabRoots on Social: Facebook: https://www.facebook.com/LabRootsInc Twitter: https://twitter.com/LabRoots LinkedIn: https://www.linkedin.com/company/labroots Instagram: https://www.instagram.com/labrootsinc Pinterest: https://www.pinterest.com/labroots/ SnapChat: labroots_inc
Просмотров: 221 LabRoots
Dr. David Agus joins “CBS This Morning: Saturday” to discuss a study published this week that analyzes the relationship between aspirin and ovarian cancer survival rates, concerns about gene editing and new tools that are getting kids interested in science. Subscribe to the "CBS This Morning" Channel HERE: http://bit.ly/1Q0v2hE Watch "CBS This Morning" HERE: http://bit.ly/1T88yAR Watch the latest installment of "Note to Self," only on "CBS This Morning," HERE: http://cbsn.ws/1Sh8XlB Follow "CBS This Morning" on Instagram HERE: http://bit.ly/1Q7NGnY Like "CBS This Morning" on Facebook HERE: http://on.fb.me/1LhtdvI Follow "CBS This Morning" on Twitter HERE: http://bit.ly/1Xj5W3p Follow "CBS This Morning" on Google+ HERE: http://bit.ly/1SIM4I8 Get the latest news and best in original reporting from CBS News delivered to your inbox. Subscribe to newsletters HERE: http://cbsn.ws/1RqHw7T Get your news on the go! Download CBS News mobile apps HERE: http://cbsn.ws/1Xb1WC8 Get new episodes of shows you love across devices the next day, stream local news live, and watch full seasons of CBS fan favorites anytime, anywhere with CBS All Access. Try it free! http://bit.ly/1OQA29B Delivered by Norah O’Donnell and Gayle King, "CBS This Morning" offers a thoughtful, substantive and insightful source of news and information to a daily audience of 3 million viewers. The Emmy Award-winning broadcast presents a mix of daily news, coverage of developing stories of national and global significance, and interviews with leading figures in politics, business and entertainment. Check local listings for "CBS This Morning" broadcast times.
Просмотров: 544 CBS This Morning
David Cohn, MD, Director of the Division of Gynecologic Oncology at the OSUCCC—James, Ohio State’s comprehensive cancer center, describes the symptoms and methods for detecting ovarian cancer, which is relatively rare, but often diagnosed in later stages. He also discusses the CA125 blood test, which is not appropriate as a screening tool, but is used to monitor a patient’s response to chemotherapy. If a woman does suspect ovarian cancer—symptoms may include abdominal pain or bloating as well as changes in bowel or urination habits—she is encouraged to visit her primary care physician for initial screening and further evaluation, which may include a pelvic ultrasound. To learn more or schedule an appointment, visit http://cancer.osu.edu/cancer-specialties/cancer-care-and-treatment/gynecologic-cancers or call 800-293-5066.
Просмотров: 796 Ohio State Wexner Medical Center
Nicoletta Colombo, MD, PhD from the European Institute of Oncology (IEO), Milan, Italy gives an overview of the Phase III ENGOT-OV16/NOVA trial of niraparib versus placebo in platinum-sensitive ovarian cancer patients (NCT01847274). Patients received either placebo or the PARP inhibitor, niraparib. Further, the trial looked at two different patient populations; one with a germline BRCA mutation (gBRCA cohort) and one without a germline BRCA mutation (non-gBRCA cohort). The trial showed a significant progression-free survival (PFS) advantage for patients in the gBRCA cohort (21 vs 5.5 months). Furthermore, there was a significant advantage in terms of PFS in the non-gBRCA cohort (9.3 vs 3.9 months). This shows that the PARP inhibitor niraparib can be used effectively for both groups of patients. Patients in the non-gBRCA cohort were also tested for homologous recombination deficiency (HRD) to determine within the sub-population, which individuals would have the best response to niraparib. Recorded at the European Society of Medical Oncology (ESMO) 2016 Congress, held in Copenhagen, Denmark.
Просмотров: 576 VJOncology
This webcast from the 19th Annual Meeting of the Network of Oncology Clinicians and Researchers (NOCR) features comprehensive reviews of the most clinically significant data in different solid tumor types including breast, lung, gastrointestinal, genitourinary, gynecologic, skin, and head and neck cancers. In this video, Dr. Robert Coleman discusses current standards of management and analyzes and interprets the most important new data that has recently modified or has the potential to modify treatment guidelines and recommendations. Earn accreditation for this activity at http://elc.imedex.com/ELC/Activity-Detail.aspx?activityid=6403 © 2012 Imedex, LLC.
Просмотров: 1147 ImedexCME
TRACO 2016: Lymphoma and Ovarian cancer Air date: Monday, September 19, 2016, 4:00:00 PM Category: TRACO Runtime: 01:47:21 Description: Lymphoma and Ovarian cancer For more information go to http://ccr.cancer.gov/trainee-resources-courses-workshops-traco Author: Kieron M. Dunleavy, M.D., NIH and Christina M. Annunziata, M.D., Ph.D., NIH Permanent link: https://videocast.nih.gov/launch.asp?19869
Просмотров: 381 nihvcast
What is germ cell ovarian cancer? Germ cell ovarian cancer is a type of ovarian cancer that originates from the germ cells of the ovary. Find more videos at http://osms.it/more. Hundreds of thousands of current & future clinicians learn by Osmosis. We have unparalleled tools and materials to prepare you to succeed in school, on board exams, and as a future clinician. Sign up for a free trial at http://osms.it/more. Subscribe to our Youtube channel at http://osms.it/subscribe. Get early access to our upcoming video releases, practice questions, giveaways, and more when you follow us on social media: Facebook: http://osms.it/facebook Twitter: http://osms.it/twitter Instagram: http://osms.it/instagram Our Vision: Everyone who cares for someone will learn by Osmosis. Our Mission: To empower the world’s clinicians and caregivers with the best learning experience possible. Learn more here: http://osms.it/mission Medical disclaimer: Knowledge Diffusion Inc (DBA Osmosis) does not provide medical advice. Osmosis and the content available on Osmosis's properties (Osmosis.org, YouTube, and other channels) do not provide a diagnosis or other recommendation for treatment and are not a substitute for the professional judgment of a healthcare professional in diagnosis and treatment of any person or animal. The determination of the need for medical services and the types of healthcare to be provided to a patient are decisions that should be made only by a physician or other licensed health care provider. Always seek the advice of a physician or other qualified healthcare provider with any questions you have regarding a medical condition.
Просмотров: 78285 Osmosis
Ovarian cancer testing has evolved in the last few years. Patients with pelvic masses and planned for surgery can benefit from being tested for multiple markers in the blood rather than just one. Learn more through this patient education video with Dr. Judith Wolf
Просмотров: 2570 ASPiRA LABS
What are sex cord-stromal ovarian cancers? Sex cord-stromal ovarian cancers are a group of cancers of the ovaries that originate from the stromal or connective tissue in the ovaries. Find more videos at http://osms.it/more. Hundreds of thousands of current & future clinicians learn by Osmosis. We have unparalleled tools and materials to prepare you to succeed in school, on board exams, and as a future clinician. Sign up for a free trial at http://osms.it/more. Subscribe to our Youtube channel at http://osms.it/subscribe. Get early access to our upcoming video releases, practice questions, giveaways, and more when you follow us on social media: Facebook: http://osms.it/facebook Twitter: http://osms.it/twitter Instagram: http://osms.it/instagram Our Vision: Everyone who cares for someone will learn by Osmosis. Our Mission: To empower the world’s clinicians and caregivers with the best learning experience possible. Learn more here: http://osms.it/mission Medical disclaimer: Knowledge Diffusion Inc (DBA Osmosis) does not provide medical advice. Osmosis and the content available on Osmosis's properties (Osmosis.org, YouTube, and other channels) do not provide a diagnosis or other recommendation for treatment and are not a substitute for the professional judgment of a healthcare professional in diagnosis and treatment of any person or animal. The determination of the need for medical services and the types of healthcare to be provided to a patient are decisions that should be made only by a physician or other licensed health care provider. Always seek the advice of a physician or other qualified healthcare provider with any questions you have regarding a medical condition.
Просмотров: 45323 Osmosis
Kunle Odunsi, MD, PhD, Deputy Director and Chair of Roswell Park's Department of Gynecologic Oncology, comments on the FDA's recent alert for ovarian cancer screening. Dr. Odunsi shares thoughts on the CA-125 test, as well as guidance for patients and cancer researchers. Read more at our blog: https://goo.gl/YkISPr
Просмотров: 138 Roswell Park Comprehensive Cancer Center
Mansoor Raza Mirza, MD, chief oncologist in the Department of Oncology in Rigshospitalet, Copenhagen University Hospital, Denmark, discusses a study of safety and dose modification for patients with low body weight receiving niraparib (Zejula) in the ENGOT-OV16/NOVA phase III trial during the 2018 Society of Gynecologic Oncology Annual Meeting. Results of this retrospective analysis showed patients who had less than 77 kg body weight and/or less than 150,000/µL platelet counts had a greater risk of grade 3 or 4 thrombocytopenia, compared to patients who were heavier and had higher platelets counts, Mirza says. Interestingly, the patients with lower body weight and platelet counts were able to remain on the 300-mg starting dose of niraparib. Only 3% of patients on the study discontinued treatment due to thrombocytopenia. These data suggest that niraparib is very manageable, dose adjustments can allow patients to remain on the drug for a long time, and lower doses likely have the same efficacy as the 300-mg dose, Mirza explains.
Просмотров: 195 OncLiveTV
Betty White received a stage 1 small cell and high-grade serous ovarian cancer diagnosis in 1997. As a former employee at The University of Texas MD Anderson Cancer Center, she knew how special the Houston, Texas-based cancer center was and decided to receive her ovarian cancer treatment here. Nearly 16 years after White's ovarian cancer diagnosis, MD Anderson continues to play a big role in her life. Not only is her daughter now a nurse here, but White also serves as a volunteer advocate in the Gynecologic Oncology Center two days a week. In that capacity, she meets with new patients and tries to share the hope she feels here. Learn about MD Anderson's Breast and Ovarian Moon Shot to end cancer: http://www.cancermoonshots.org/moon-shots/breast-ovarian/
Просмотров: 122 MD Anderson Cancer Center
Joyce A. O'Shaughnessy, MD, Breast Cancer Research, Baylor Sammons Cancer Center in Dallas, TX, begins by mentioning that the HER2 marker is already a focused part of breast cancer. She believes that some biomarker selection will become necessary and that it is no longer feasible to approach the adjuvant setting with a mixed population of patients with triple-negative breast cancer and indolent ER-positive breast cancer. O'Shaughnessy believes it is not feasible to find a selection marker for everything, but she believes some selection needs to take place. There is a great deal of systems biology that comes into play when dealing with breast cancer. Because of its complex nature it may not be possible to know every operative pathway and microenvironment, at this time, but a basic understanding of the biology is needed Future selection of patients may also be based not only on a positive outcome but also a negative. If you know a patient will not respond positively because they posses a certain marker you may exclude them from studies. Using biomarkers in this way can be just as useful as a positive outcome. There is currently a great deal of effort being focused on discovering very narrow subsets of patients, and this will produce some success, but in the long run O'Shaughnessy believes broader based biological subsets will be more successful.
Просмотров: 201 OncLiveTV
September is ovarian cancer awareness month here is the United States. Ovarian cancer is a cancer that develops in the ovaries. This cancer in the female reproductive organ is sometimes called the silent killer because in many cases the disease is not discovered until the cancer has spread. Joining VOA’s health correspondent Linord Moudou to discuss the subject is our colleague Clara Frenk, a VOA TV producer, who was diagnosed with ovarian cancer in 2013 and underwent treatment successfully. Clara shares her experience.
Просмотров: 125 TV2Africa
Panelists Bradley J. Monk, MD; Thomas Herzog, MD; Angeles Alvarez Secord, MD; Robert L. Coleman, MD; and Kathleen N. Moore, MD, provide insight on the evidence for using dose-dense chemotherapy and adding bevacizumab in ovarian cancer.
Просмотров: 528 OncLiveTV
The panelists, Daniel G. Haller, MD, and Charles S. Fuchs, MD, MPH, provide examples of prognostic and predictive markers in colorectal cancer and their utility in treatment decisions.
Просмотров: 289 OncLiveTV
2nd Annual Nanomedicine Symposium, July 15th 2017, Cambridge MA Frank Slack, Beth Israel Deaconess Medical Center Cancer Center/Harvard Medical School
Просмотров: 453 PrecisionNanoSystems
This video is intended for non-US residents. A lung cancer patient's cancer cells must have the target for targeted therapy to be most effective. To determine if a patient's cancer cells have a specific target, such as an EGFR mutation, a biomarker analysis is performed in a laboratory by a pathologist on the patient's biopsy tissue sample. For more information on lung cancer and lung cancer treatments, visit: http://www.lifewithlungcancer.info
Просмотров: 152 LifeWithLungCancer
Ursula Matulonis, MD of the Dana-Farber Cancer Institute, Boston, MA talks about the ENGOT-OV16/NOVA trial, a trial of women with relapsed platinum-sensitive high-grade ovarian cancer (NCT01847274). Dr Matulonis explains that this was randomized, double-blinded placebo study; the women were platinum-sensitive and responding to platinum and went on to niraparib versus placebo. They also underewent germline BRCA testing and were grouped into gBRCA and non-gBRCA cohort; in the latter cohort, they were further tested for homologous recombination deficiency (HRD). In all the groups, there was a benefit to receiving niraparib and this is not a suprising result as Dr Matulonis explains.
Просмотров: 340 VJOncology
Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses surgical readmission and survival in patients with ovarian cancer. Neoadjuvant chemotherapy has been shown to decrease surgical morbidity, lowering the complication rates and risk of death.
Просмотров: 44 Targeted Oncology
Best of the Day: from the 2014 Society of Gynecologic Oncology's (SGO) 45th Annual Meeting on Women's Cancer Dr. Bradley Monk is joined by four outstanding gynecologic cancer experts to review the emerging data from the 45th SGO Annual Meeting on Women's Cancer 2014 in Tampa, Florida. Topics include the latest on clinical trial research, advances in surgical care and translational research, and the current state of the art therapeutics in cervical, uterine, and ovarian cancers. Earn accreditation for this activity at the following location: http://elc.imedex.com/elc/activity-search.aspx?search=7051 © 2014 Imedex, LLC.
Просмотров: 840 ImedexCME
Dr. Singh describes CA-125 and shares how CA-125 assays are useful for monitoring ovarian cancer. For more information on ovarian cancer visit http://www.empowher.com/condition/ovarian-cancer.
Просмотров: 16235 EmpowHER
Panelists Adam M. Brufsky, MD, PhD; Carlos L. Arteaga, MD; Debu Tripathy, MD; José Baselga, MD, PhD; Kimberly L. Blackwell, MD; and Denise A. Yardley, MD, review the evidence to date for using immunotherapy for breast cancer, preliminary data for immunoconjugates and checkpoint inhibitors, and potential predictive biomarkers.
Просмотров: 856 OncLiveTV
Prof Swisher (University of Washington, Washington, USA) talks to ecancertv at the 26th EORTC-NCI-AACR Symposium about data from a phase II trial, ARIEL2, which aims to identify patients with ovarian cancer likely to respond to rucaparib.
Просмотров: 113 ecancer
Macuks R, Baidekalna I, Donina S. Comparison of different ovarian cancer detection algorithms. Eur J Gynaecol Oncology, 2011; 32(4):408-10. Macuks R, Baidekalna I, Donina S. Diagnostic test for ovarian cancer composed of ovarian cancer symptom index, menopausal status and ovarian cancer antigen CA125. Eur J Gynaecol Oncology, 2011; 32(3):286-8. Macuks R, Baidekalna Ieva, Avdejeva Arina, Gritcina Julia, Donina Simona. Comparison of Two Novel Biomarker Panels in Ovarian Cancer Diagnosis for Patients with a Pelvic Mass. Eur J Clinical and Medical Oncology, 2011; 3:79-83. Ronalds Macuks, Ieva Baidekalna, Ella Nesterenko, Renate Renemane, Simona Donina. Evaluation of ovarian cancer symptom index. RSU Research articles in Medicine & Pharmacy - Collection of Scientific papers, 2009:63-68. Ronalds Macuks, Ieva Baidekalna, Julija Gritcina, Arina Avdejeva, Simona Donina. Apolipoprotein A1 and transferrin as biomarkers in ovarian cancer diagnostics. Acta Chirurgica Latiensis, 2010:16-20. Ronalds Mačuks, Ludmila Eņgele, Inta Nuķe, Agnese Sudraba, Simona Doniņa. Comparative Analysis of Insulin-like Growth Factor I and Tumour-associated Antigens in Cancer Patients at the Time of Diagnosis. Proceedings of the Latvian Academy of Sciences. Section B, 2009; 4:186--190. Ronalds Macuks, Ieva Baidekalna, Inta Nuke, and Simona Donina. Role of combined soluble interleukine-2 receptor alpha and CA125 serum marker assay for detection of ovarian cancer. Proceedings of Latvian Academy of Sciences. Section B, 2011; 1:20--30. Ronalds Macuks, Ieva Baidekalna, Inta Nuke, Ludmila Engele, Simona Donina. Ovarian cancer specificity of combined biomarker assay consisting of soluble interleukine-2 receptor alpha and CA125. RSU Research articles in Medicine & Pharmacy - Collection of Scientific papers, 2010:66-72. Ronalds Mačuks, Ludmila Eņgele, Inta Nuķe, Agnese Sudraba, Simona Doniņa. Comparative Analysis of Insulin-like Growth Factor I and Tumour-associated Antigens in Cancer Patients at the Time of Diagnosis. Proceedings of the Latvian Academy of Sciences. Section B, 2009; 4:186--190. Gultekin M, Dursun P, Vranes B, Laky R, Bossart M, Grabowski JP, Piek JM, Manchanda R, Grimm C, Dallaku K, Babloyan S, Moisei A, Van Gorp T, Cadron I, Markov P, Micevska A, Halaska M, Steffensen KD, Gristsenko L, Nissi R, Lambaudie E, Tsitsishvili Z, Haidopoulos D, Tsolakidis D, Novak Z, Peiretti M, Dunenova G, Macuks R, Hetland TE, Michelsen TM, Martins FC, Achimas-Cadariu P, Ulrikh EA, Uharcek P, Malic S, Ognjenovic D, Zapardiel I, Johann S, Sukhin VS, Manchanda R. Gynecologic oncology training systems in Europe: a report from the European network of young gynaecological oncologists. Int J Gynecol Cancer. 2011 Nov;21(8):1500-6. Rezeberga D, Macuks R. Ovarian cancer: When we should stop treatment and go beyond with only palliative care? Chapter 190, 2nd ed. Textbook of Gynecological Oncology 2011. Ronalds Macuks, Halis Özdemir, Polat Dursun, Özlem Işıksaçan Özen, Nihan Haberal, Ali Ayhan. Malignant intraperitoneal mesothelioma-Başkent University experience. J Turkish-German Gynecol Assoc, 2011; 12: 104-9. Halis Özdemir, Ronald Macuks, E. Didem Özdemir, Polat Dursun, Özden Altundağ, Ali Ayhan. Borderline Tumor Tumorlerinde Guncel Yaklasimlar. Türk Jinekolojik Onkoloji Dergisi. Haziran 2010, Cilt 13, Say 2, Sayfa 27-35.
Просмотров: 1584 Onkoklīnika Tallinas ielā 1,Rīgā
Robert L. Coleman, MD, FACOG, FACS, professor, Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, vice chair, Clinical Research, The University of Texas MD Anderson Cancer Center, discusses the results of the ARIEL2 trial, a phase II study to identify patients with ovarian cancer likely to respond to rucaparib using tumor genetic analysis.
Просмотров: 405 Targeted Oncology
This video celebrates the accomplishments and contributions of The Cancer Genome Atlas, a landmark program in cancer genomics. As the TCGA program comes to a close, the video relives the driving forces behind the creation of the program, innovations employed in its execution, and major impacts the program has made on approaches to cancer research, with reflections from some of the significant figures in the program’s inception and management. https://www.cancer.gov/about-nci/organization/ccg audio described version: https://youtu.be/zxyWidFVjjk
Просмотров: 1479 National Cancer Institute
Julie is an ovarian cancer surivivor coming up on her 5 years of being cancer free. She shares how important it is for women to advocate for themselves and what ovarian cancer awareness means to her. Take a short quiz to find out if you're at risk: http://bit.ly/1O2f1uN
Просмотров: 159 MySupport360 Hereditary Cancer
Dr. William E. Haskins Seminar Series: Accelerated Protein Biomarker Discovery with Microwave & Magnetic (M2) Proteomics
Просмотров: 154 RCMI Program UPR Medical Sciences Campus
Robert L. Coleman, MD, FACOG, FACS, professor, Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, vice chair, Clinical Research, The University of Texas MD Anderson Cancer Center, discusses the next steps following results of the ARIEL2 trial, which aimed to identify patients with ovarian cancer most likely to respond to rucaparib using tumor genetic analysis.
Просмотров: 243 OncLiveTV
Dr. David Gershenson discusses Unraveling Ovarian Cancer: New Treatment Of Rare Sub-types, at Ovarcome Annual Zeal For Teal Luncheon, 2017
Просмотров: 64 Ovarcome Non-Profit
(September 4, 2008) Paul Norman, DS, FRACS, discusses several different types of biomarkers, both chemical and genetic, and the need for greater instances of replication and screening to find more conclusive evidence for therapeutic methods. 2008 Stanford AAA Summit http://vascular.stanford.edu/news/summit.html Stanford School of Medicine http://med.stanford.edu/ Stanford Channel on YouTube: http://www.youtube.com/stanford
Просмотров: 4095 Stanford
How to treat Recurrent Cancer Current treatment of recurrent cancer is not optimal since medicine ignores that organism resists the tumor. Host resistance may be weak yet it is significant. Obviously if host resistance is high patient requires less drugs and vice versa. Here is an example of therapy which considers host resistance. A woman leaving mammography with a localized breast tumor is treated and tumor is removed. In most women treatment will leave behind tumor remnants too small to be detected. They will grow and later on present as recurrent tumors. The question is how to treat them optimally? I maintain that breast cancer is driven by a virus to which it responds with a tumor. During an aggressive virus infection tumor grows faster and vice versa. I regard tumor as biomarker of two processes: 1. Severity of virus infection 2. Host resistance. Once cancer recurs it is essentially incurable, and the only therapeutic objective is dormancy induction. Cancer dormancy has two manifestations: 1. Tumor stops growing or grows extremely slowly. 2. Tumor is invisible Dormancy induction requires small drug doses. You start with a small dose. Rise it gradually until dormancy is achieved. The initial small dose depends on the time of tumor recurrence. The later tumor recurs the smaller dose is needed
Просмотров: 1237 Gershom Zajicek M.D,